

January 12, 2023

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai: 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai: 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Statement of Investor Complaints

Pursuant to Regulation 13 (3) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find below the statement of Investor complaints for the quarter ended December 31, 2022:

Sr. No	Particulars	Details
1	No. of Investor Complaints pending at the beginning of the quarter	00
2	No. of Investor Complaints received during the quarter	00
3	No. of Investor Complaints disposed off during the quarter	00
4	No. of Investor Complaints those remaining unresolved at the end of the quarter	00

Please take the same on records.

Yours Faithfully,

For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer